Surgery Hygiene News
-
Infection Control Resources to Identify Klebsiella and Other Pathogens in Healthcare Settings throughout Puerto Rico
The Centers for Disease Control and Prevention (CDC) describes Klebsiella as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). These include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. The agency warns Klebsiella bacteria have increasingly developed antimicrobial resistance, most recently to the ...
-
Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...
-
Klebsiella in Healthcare Settings Discussed in New Online Video
The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses Klebsiella, a type of gram-negative bacteria that can cause various healthcare-associated infections (HAIs). “HAIs due to Klebsiella can include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis,” said ...
-
Caresyntax and Sheba ARC Sign Agreement to Develop the Future Model for Surgical Innovation
Caresyntax, the leading vendor-neutral enterprise surgical data and intelligence platform designed to make surgery smarter and safer by converging AI-powered software, devices, and clinical services, today announced a partnership with ARC (Accelerate, Redesign, Collaborate) Sheba’s Global Innovation platform to establish and replicate the ARC Surgical Innovation Model using the Caresyntax ...
By Caresyntax
-
XF-73 Nasal Phase 3 development plans finalised
Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...
-
7 December 2022 - FDA/CDC highlight need for infection preventions
Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...
-
XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...
-
Ondine reports successful US Phase 2 trial data
Results show a single, 5-minute treatment of nasal photodisinfection significantly reduces Staphylococcus aureus, a major cause of surgical site infections, in pre-surgical patients Top line results met primary endpoint and showed nasal photodisinfection eliminated or significantly decreased Staphylococcus aureus ( aureus) in 92% of carriers treated per protocol (P<0.001). All of the 319 ...
-
Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients
The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), with 70% of patient samples completely inactivated from a single 5-minute treatment. The nose is the primary location for SARS-CoV-2 entry and it has a central role in transmission and disease severity. The Journal ...
-
Ondine completes enrollment for US Phase II nasal photodisinfection trial
Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s nasal photodisinfection technology eradicates pathogens – specifically Staphylococcus aureus – in the nose. The single-center, BENEFIT-aPDT open-label study is being carried out at HCA Healthcare’s ...
-
Caresyntax & Intel Collaborate to Address Surgical Staffing Shortage
Combining capabilities to develop breakthrough technologies for transforming surgery. Hospitals and Surgery Centers face many challenges in surgery as they work to recover from COVID. Directors of Perioperative Services, Surgeons, OR Staff and OR managers are facing high levels of stress with maintaining quality patient care, increasing surgical case volume from backlogs, while at the same time ...
By Caresyntax
-
Imbed’s Microlyte Matrix Added to VA’S IDIQ Contract
Imbed Biosciences Inc. (Imbed), a developer of next-generation therapies for tissue repair, and Spartan Medical, a veteran-owned Federal Contractor with fourteen years of flawless performance, jointly announced today that Imbed’s Microlyte® Matrix wound dressing portfolio has been added to Spartan Medical’s VA IDIQ Contract with the U.S. Department of Veteran Affairs (VA). The ...
-
Versius surgical robot used for first time in an Italian public hospital
CMR Surgical (CMR) – a global surgical robotics business – today announced the introduction of the Versius® Surgical Robotic System, at Policlinico di Milano, a leading research hospital and care institute (IRCCS), and one of the largest healthcare facilities in Lombardy, Italy. Within the hospital, Versius will be used in a multi-specialty robotics programme including thoracic ...
-
Takeover of terraplasma medical GmbH by the Viromed Group
The majority takeover of terraplasma medical GmbH by Viromed Plasma GmbH, a member of the Viromed Group, was announced today. terraplasma GmbH will continue to hold shares in terraplasma medical GmbH in order to contribute its expertise in the field of cold atmospheric plasmas in the future. The common goal of Viromed and terraplasma is to establish terraplasma medical as the world's leading ...
-
Microlyte SURGICAL Associated with Positive Outcomes in Prospective Clinical Case Series in Patients at Risk for Surgical Site Infection
Imbed Biosciences, Inc. (Imbed), a privately held biotech company emerging as a leader in advanced wound care, announced today the results of a prospective clinical evaluation of its next-generation wound Matrix, Microlyte® SURGICAL, in diabetic patients undergoing foot and ankle surgery who would ordinarily be at risk of a surgical site infection. Results will be published in the October ...
-
Equine Today: The Importance of Having a Biosecurity Program at your Practice
Fluxergy’s is launching its environmental salmonella assay where equine practices and facilities can add in-house PCR testing to their biosecurity program. This avoids central lab processing and allows clinicians to clear stalls after simple overnight enrichment. Contact Sales What is Biosecurity? Biosecurity describes all the human actions that go into preventing disease in horses and ...
By Fluxergy
-
Next Science to Exhibit Surgical Product Portfolio at AAOS 2021
Next Science Limited (ASX:NXS), an innovative medical technology company, announced that it will exhibit at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting and conference in San Diego, California, from Aug. 31 – Sept. 3. Next Science, whose mission is to heal patients and save lives by addressing the impact of biofilms on human health, will exhibit at Booth No. 5035. ...
-
Aatru Medical, LLC submits NPSIMS product to FDA for Class II Clearance and completes Series C funding
Aatru Medical, LLC ("Aatru") is pleased to announce its recent submission to the FDA of a traditional 510(k) premarket notification application for the company's first product, NPSIMS - Negative Pressure Surgical Incision Management System. The submission efforts were led by Aatru President and Board Member Edward Armstrong, in conjunction with Coastal Consulting Group, NAMSA, and DuVal & ...
-
TISSIUM Awarded 2.2M€ from i-Nov Competition to Address Chronic Rhinosinusitis
TISSIUM, a privately-owned life science company developing fullysynthetic, biomorphic programmable polymers, announced today it has been awarded 2.2M€ in financing that will accelerate its development of a drug-eluting tissue adhesive to address the unmet needs of Chronic Rhinosinusitis (CRS) patients. The funding comes from the Investments for the Future program (Programme ...
By TISSIUM
-
Molecular Matrix, Inc. Forms Strategic Alliance with Philosys Healthcare
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you